New Drug Combination Shows Promise for Blood Cancer Patients in Major Trial

The New England Journal of Medicine (@NEJM) has shared findings from the MonumenTAL-3 trial, a phase 3 study — meaning a large-scale test in human patients, the stage before a drug can typically be approved for routine use — examining whether adding talquetamab to existing treatment improves survival and response rates in people with multiple myeloma (a type of blood cancer affecting plasma cells in the bone marrow) who had already undergone previous treatment.

Talquetamab is a bispecific antibody, a drug designed to attach to two different targets at once — in this case, directing the body’s immune cells to attack cancer cells. The MonumenTAL-3 trial is specifically focused on patients whose myeloma had returned or stopped responding to earlier therapies, a group for whom treatment options can be limited.

The journal summarised the trial findings in a short video format. Full details of the results, including specific response rates or survival data, were not disclosed in the post itself.

Multiple myeloma is not among the most common cancers, but it remains difficult to treat in later stages. Any phase 3 evidence of improved outcomes in previously treated patients would be relevant to haematology (blood disorder) specialists across the NHS.

Kent residents with concerns about blood cancer symptoms — which the NHS says can include bone pain, fatigue, frequent infections, and unusual bruising — should contact their GP in the first instance, or call NHS 111 for guidance.

Key information

• GP referral: Anyone concerned about possible blood cancer symptoms should speak to their GP
• NHS 111: Available 24 hours a day for health advice when your GP is not available
• Emergencies: Call 999 or go to your nearest A&E